Abstract
Locally advanced esophageal cancer (EC) remains a disease with poor prognosis, with a 5-year survival of around 40%. In 2012, the CROSS trial was a changing point in the treatment of EC by introducing neoadjuvant (NA) chemoradiotherapy (CRT), with carboplatin/paclitaxel and reduced-dose RT (41.4Gy), as a valid approach, with higher disease-free survival (DFS) and overall survival (OS) than had been seen before. These results had subgroup variations, with better OS in squamous cell carcinoma (SCC) patients when compared to adenocarcinoma (AC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
